Search research articles
Contact Us
Filters
Showing results (421-430 of 484) with videos related to
Page
of 49
Sort By:
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
Hypertension (Dallas, Tex. : 1979)
|
September 9, 2010
Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage
Hisatomi Arima, Craig S Anderson, Ji Guang Wang, et al.
Journal of the American College of Cardiology
|
October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, George Bakris, Christopher P Cannon, et al.
International Journal of Cardiology
|
January 7, 2016
Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries
Ruth Webster, Anushka Patel, Vanessa Selak, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
International Journal of Cardiology
|
October 23, 2013
Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration
Ruth Webster, Anushka Patel, Laurent Billot, et al.
Journal of Hypertension
|
November 13, 2025
Potassium-enriched salt for patients with hypertension: a Hypertension Australia and National Hypertension Taskforce of Australia Position Statement
Xiaoyue Xu, Mary-Anne Land, Sharon James, et al.
Journal of Epidemiology and Community Health
|
December 8, 2020
Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS)
Liping Huang, Jie Yu, Bruce Neal, et al.
Page
of 49
Search research articles
Search
Showing results (421-430 of 484) with videos related to
Sort By:
Page
of 49
Circulation
|
November 12, 2019
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, et al.
Hypertension (Dallas, Tex. : 1979)
|
September 9, 2010
Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage
Hisatomi Arima, Craig S Anderson, Ji Guang Wang, et al.
Journal of the American College of Cardiology
|
October 27, 2022
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, George Bakris, Christopher P Cannon, et al.
International Journal of Cardiology
|
January 7, 2016
Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries
Ruth Webster, Anushka Patel, Vanessa Selak, et al.
European Heart Journal
|
August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
American Heart Journal
|
December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
Ashish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International
|
December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
Megumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
International Journal of Cardiology
|
October 23, 2013
Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration
Ruth Webster, Anushka Patel, Laurent Billot, et al.
Journal of Hypertension
|
November 13, 2025
Potassium-enriched salt for patients with hypertension: a Hypertension Australia and National Hypertension Taskforce of Australia Position Statement
Xiaoyue Xu, Mary-Anne Land, Sharon James, et al.
Journal of Epidemiology and Community Health
|
December 8, 2020
Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS)
Liping Huang, Jie Yu, Bruce Neal, et al.
Page
of 49